Does tirzepatide help with weight loss — and how well does it actually work?

The misconception: tirzepatide is just another appetite suppressant

A common assumption is that tirzepatide works the same way as older appetite suppressants, reducing hunger through a single channel and producing modest results. That framing undersells the biology considerably. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it acts on two separate gut-hormone receptors at once. GLP-1 slows the rate at which food leaves the stomach and signals fullness to the brain; GIP adds a second layer of appetite regulation through a different receptor pathway. No other weight-loss medicine currently licensed in the UK works across both simultaneously.

What this means in practice is that people on tirzepatide typically feel less hungry, feel full sooner, and find food less compelling overall. The effect builds gradually as the dose is titrated upward by the prescriber, starting at 2.5mg (a dose chosen to let the body adjust) before stepping up in stages toward the therapeutic range. If you want a closer look at the underlying mechanism, our page on how Mounjaro helps with weight loss covers the biology in more detail.

Understanding the dual mechanism also explains why the trial results look different from earlier GLP-1 medicines. The weight loss is not a side effect of reducing blood sugar; it is the primary pharmacological action.

What the SURMOUNT-1 trial actually found

The strongest evidence for does tirzepatide make you lose weight comes from SURMOUNT-1, a 72-week phase 3 trial published in the New England Journal of Medicine. The trial enrolled 2,539 adults with obesity who did not have type 2 diabetes. Participants received tirzepatide at 5mg, 10mg, or 15mg alongside lifestyle support, or a placebo. At the 15mg dose, average body-weight reduction was around 20–21%. At 10mg, the average was roughly 19%; at 5mg, around 15%. All three doses outperformed placebo by a significant margin.

These are averages across thousands of participants, so individual results will vary. Some people lose more; some less. The trial ran for over a year, and weight loss continued well beyond the early weeks, unlike calorie restriction alone, where plateau effects are common and early. The SURMOUNT-5 trial later compared tirzepatide directly against semaglutide 2.4mg (Wegovy) over 72 weeks in a head-to-head trial, and tirzepatide produced greater average weight reduction. NICE cited this evidence in its December 2024 appraisal of tirzepatide, TA1026, which recommended it for NHS use in eligible adults.

One thing worth keeping in mind: weight regain after stopping is common with any GLP-1 medicine. These treatments work while you take them; they are not a permanent metabolic reset. Our prescribers are straightforward about this from the start.

Who the evidence applies to, and who it does not

The SURMOUNT-1 trial recruited adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That broadly mirrors the UK licensed eligibility criteria for tirzepatide as a weight-management medicine. Eligible weight-related conditions include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, and cardiovascular disease, among others. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance, a prescriber will check this during consultation.

BMI alone does not determine suitability. A prescriber also considers your medical history, current medicines, and any contraindications. People who are pregnant, breastfeeding, or trying to conceive should not use tirzepatide; the same applies to anyone under 18. Certain conditions, including a history of medullary thyroid carcinoma or a specific type of multiple endocrine neoplasia, mean tirzepatide is not appropriate. For those wondering more broadly whether they are likely to be eligible, the page on whether Mounjaro is likely to be right for you walks through the key factors.

The evidence is strong. Whether it applies to your individual situation is a clinical question, and one a prescriber is best placed to answer.

Practical realities: what people on tirzepatide typically experience

Most people notice appetite changes within the first few weeks. Hunger signals quiet down; portions that felt normal before feel too large. Nausea is the most frequently reported side effect, particularly in the early weeks or after a dose increase. It is usually mild to moderate and settles as the body adjusts. Other commonly reported effects include constipation, diarrhoea, reflux, and fatigue. These are covered in detail on the tirzepatide information page; if you ever have severe, persistent stomach pain that spreads to your back, that needs prompt medical attention and you should contact a healthcare professional without delay.

The injection itself is once a week, via a pre-filled KwikPen. Many people describe the routine as straightforward once they have done it a few times, storing the pen in the fridge, injecting on the same day each week, rotating between sites on the abdomen, thigh, or upper arm. The guide to getting the most from tirzepatide covers the practical side, including diet and activity alongside treatment.

The evidence on how tirzepatide helps people lose weight is now well-established. Getting the most from it still takes a clinical assessment, a proper supply chain, and honest ongoing support. If you'd like to see whether you might be eligible, check your eligibility with our prescribers, the consultation is free.